Brad Newhouse

This inventor holds 20 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Cancer Therapeutics. Top assignees: Array Biopharma Inc., Genentech, Inc., Mirati Therapeutics, Inc.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brad Newhouse. Retrieved from https://idiyas.com/inventor/brad-newhouse

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 3)

% Patents Active = 50.0

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 13)

Average Co-Inventor Count = 11.2

ph-index = 5

Forward Citations = 58(Granted Patents)

Location History:

Broomfield, CO (US) (2009)
Boulder, CA (US) (2017)
Boulder, CO (US) (2012 - 2024)

Company Filing History:

Mirati Therapeutics, Inc.

patents

4. 3 out of 10

Ventirx Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

KRas G12D Inhibitors

Bicyclic Fused Pyridine

Type III Receptor Tyrosine Kinase

Serine/Threonine Kinase

TrkA Kinase Inhibitors

Toll-Like Receptor Modulators

Raf Inhibitors

Pyrazole Compounds

Imidazopyrazines

Substituted Benzoazepines

Cancer Treatment

Pharmaceutical Compounds

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747253 - KRas G12D inhibitors (2026-09-29),

2. 12630566 - KRas G12D inhibitors (2026-05-19),

3. 11964989 - KRas G12D inhibitors (2024-04-23),

4. 11453683 - KRas G12D inhibitors (2022-09-27),

5. 11247990 - Bicyclic fused pyridine compounds as inhibitors of TAM kinases (2022-02-15),

6. 10669269 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2020-06-02),

7. 10647715 - KRas G12C inhibitors (2020-05-12),

8. 10154995 - Serine/threonine kinase inhibitors (2018-12-18),

9. 9969694 - N-(arylalkyl)-N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors (2018-05-15),

10. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2017-11-07),

11. 9763942 - Serine/threonine kinase inhibitors (2017-09-19),

12. 9670208 - Serine/threonine kinase inhibitors (2017-06-06),

13. 9655904 - Substituted benzoazepines as toll-like receptor modulators (2017-05-23),

14. 9174981 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2015-11-03),

15. 9126940 - Substituted benzoazepines as toll-like receptor modulators (2015-09-08),

Title: Unveiling the Innovative Mind of Brad Newhouse

Introduction:

Brad Newhouse, a prolific inventor hailing from Boulder, CO (US), has made significant strides in the field of pharmaceutical innovations. With a remarkable portfolio of 18 patents to his name, Brad is a trailblazer in developing compounds that inhibit the activity of KRas G12D, particularly in the treatment of cancer.

Latest Patents:

Among his latest patents are the KRas G12D inhibitors – compounds designed to effectively combat the activity of KRas G12D. These compounds, characterized by a distinct structure represented by Formula (I) or its pharmaceutically acceptable salt, hold immense promise in the realm of cancer treatment.

Career Highlights:

Brad Newhouse's exemplary career has been intertwined with esteemed companies such as Array Biopharma Inc. and Genentech, Inc., where his groundbreaking research has left an indelible mark. His innovative approach to pharmaceutical compositions and methods of treatment underscores his commitment to advancing healthcare solutions.

Collaborations:

Throughout his career, Brad has collaborated with esteemed professionals such as James F Blake and Joseph P Lyssikatos. Together, they have synergized their expertise to drive forward cutting-edge research and development in the field of oncology and drug discovery.

Conclusion:

In conclusion, Brad Newhouse stands as a beacon of innovation in the world of pharmaceuticals. His relentless pursuit of novel compounds and treatment modalities signifies a commitment to revolutionizing cancer care. With a stellar track record and a visionary approach, Brad continues to inspire future generations of inventors and researchers in the quest for transformative healthcare solutions.

Profile summary based on public USPTO records.